Major investments in life science capabilities and Swedish healthcare have been made during recent years and more will follow. Cutting edge research infrastructure are already largely in place. New Karolinska Solna, part of a multi-billion Euro investment in infrastructure, will be inaugurated in the autumn of 2016. AstraZeneca will build a new 225 million Euro manufacturing facility for biologics and GE Healthcare have announced a 90 million Euro investments in their protein purification production. The government, a private foundation and AstraZeneca will jointly invest in biologics and a number of other initiatives across the country are under way.

The Swedish government has made major investments in the country’s life sciences research infrastructure with the aim to enable cutting edge research and development of life science solutions. 


In anticipation of continued growth in biologics, two global giants, AstraZeneca and GE Healthcare have chosen Sweden for their next investments in capacities for protein-based pharmaceuticals.

Sweden aims at strengthening its existing competitive edge in protein science further through two new initiatives, one is a consortium between the Swedish government, AstraZeneca and Sweden’s leading, private, research funding body the Knut and Alice Wallenberg Foundation. The second is a government funded program focusing on biologics. 


A 1,5 billion Euro investment in a new hospital complex

New Karolinska Solna (NKS) is the project name for the state-of-the-art hospital currently under construction next to Karolinska University Hospital in Solna. The assignment for the new university hospital, which will open its doors to the first patients at the end of 2016, is to provide highly specialized healthcare to the 2.5 million population in the region and to conduct basic research, patient-focused clinical research as well as education. Greater collaboration between healthcare and research will contribute to new research findings being turned into new treatment methods and medicines faster.

Go to Nya Karolinska Solna

Stockholm Life – a hub for life science in central Stockholm

Located in central Stockholm, the city’s largest ever development project, Hagastaden, is well underway. The area is devoted to life science and encompasses all the elements required to become a true international hub. Karolinska Institutet, KTH Royal Institute of Technology, Stockholm University, SciLifeLab, Stockholm School of Economics and the existing and new Karolinska University Hospital are all within walking distance. This means that within a radius of two kilometres, there are four major universities, some of the world’s best clinical research facilities, leading healthcare providers, and one of Europe’s highest concentrations of life science companies, organisations and institutes.

Investments in clusters across Sweden

Major investments in clusters, life science and healthcare facilities are also under way in other cities in Sweden. Examples include:

  • The Skandion Clinic in Uppsala, the first clinic for proton therapy in Scandinavia. The first patient was treated in 2015.
  • Re-building and expansion of Uppsala University Hospital, planned to be ready by 2022. A major investment of approximately 600 million Euros.
  • A new Centre for Imaging and Intervention at Sahlgrenska University Hospital in Gothenburg, a 200 million Euro investment, due for completion in 2016.
  • A new hub for biomedical translational research (Sahlgrenska Life) at Northern Europe´s largest hospital, in central Gothenburg. At an early stage of development, the core concept is to create an environment for seamless collaboration between industry, healthcare, research and education.
  • In Lund, the Max IV and ESS investments in physical research infrastructure for use in several scientific branches exceed 2 billion Euros.
  • A new Medical Biology Centre (MBC) at Umeå University enabling the Faculty of Medicine to co-locate its activities and gather its medical cutting edge research under one roof. An investment of almost 30 million Euros.